InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.855
-0.055 (-2.88%)
At close: Jul 17, 2026, 4:00 PM EDT
1.904
+0.049 (2.66%)
After-hours: Jul 17, 2026, 5:18 PM EDT
InflaRx Revenue
InflaRx had revenue of 29.33K EUR in the twelve months ending March 31, 2026, down -77.39% year-over-year. In the year 2025, InflaRx had annual revenue of 29.33K, down -82.31%.
Revenue (ttm)
29.33K EUR
Revenue Growth
-77.39%
P/S Ratio
8,079.13
Revenue / Employee
451 EUR
Employees
65
Market Cap
273.23M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29.33K | -136.46K | -82.31% |
| Dec 31, 2024 | 165.79K | 102.70K | 162.79% |
| Dec 31, 2023 | 63.09K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 130.42M |
| Bicycle Therapeutics | 63.50M |
| Lineage Cell Therapeutics | 14.78M |
| Opus Genetics | 11.98M |
| SAB Biotherapeutics | 114.70K |
IFRX News
- 17 days ago - InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos - GlobeNewsWire
- 2 months ago - InflaRx upgraded to Strong Buy from Outperform at Raymond James - TheFly
- 2 months ago - InflaRx price target raised to $8 from $6 at H.C. Wainwright - TheFly
- 2 months ago - InflaRx Transcript: Investor update - Transcripts
- 2 months ago - InflaRx Press release: Investor update - Filings
- 2 months ago - InflaRx Slides: Investor update - Filings
- 2 months ago - InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares - GlobeNewsWire
- 2 months ago - InflaRx to develop izicopan in AAV - TheFly